🇺🇸 Ketorolac Tromethamine Injection in United States
51 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 51
Most-reported reactions
- Acute Kidney Injury — 18 reports (35.29%)
- Anaphylactic Reaction — 7 reports (13.73%)
- Dizziness — 4 reports (7.84%)
- Product Use In Unapproved Indication — 4 reports (7.84%)
- Acute Hepatic Failure — 3 reports (5.88%)
- Condition Aggravated — 3 reports (5.88%)
- Drug Interaction — 3 reports (5.88%)
- Hypotension — 3 reports (5.88%)
- Product Use Issue — 3 reports (5.88%)
- Renal Infarct — 3 reports (5.88%)
Frequently asked questions
Is Ketorolac Tromethamine Injection approved in United States?
Ketorolac Tromethamine Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ketorolac Tromethamine Injection in United States?
UConn Health is the originator. The local marketing authorisation holder may differ — check the official source linked above.